Most women with early‐stage breast cancer are prescribed adjuvant endocrine therapy (AET, e.g., tamoxifen, aromatase inhibitors) to reduce the risk of cancer recurrence and mortality (Early Breast Cancer Trialists Collaborative Group, 2011, 2015). This evidence concerns the gene CYP19A1 and breast cancer.